[HTML][HTML] Targeting fatty acid metabolism in glioblastoma

J Miska, NS Chandel - The Journal of Clinical Investigation, 2023 - Am Soc Clin Investig
The Journal of Clinical Investigation, 2023Am Soc Clin Investig
Glioblastoma (GBM) is a primary tumor of the brain defined by its uniform lethality and
resistance to conventional therapies. There have been considerable efforts to untangle the
metabolic underpinnings of this disease to find novel therapeutic avenues for treatment. An
emerging focus in this field is fatty acid (FA) metabolism, which is critical for numerous
diverse biological processes involved in GBM pathogenesis. These processes can be
classified into four broad fates: anabolism, catabolism, regulation of ferroptosis, and the …
Glioblastoma (GBM) is a primary tumor of the brain defined by its uniform lethality and resistance to conventional therapies. There have been considerable efforts to untangle the metabolic underpinnings of this disease to find novel therapeutic avenues for treatment. An emerging focus in this field is fatty acid (FA) metabolism, which is critical for numerous diverse biological processes involved in GBM pathogenesis. These processes can be classified into four broad fates: anabolism, catabolism, regulation of ferroptosis, and the generation of signaling molecules. Each fate provides a unique perspective by which we can inspect GBM biology and gives us a road map to understanding this complicated field. This Review discusses the basic, translational, and clinical insights into each of these fates to provide a contemporary understanding of FA biology in GBM. It is clear, based on the literature, that there are far more questions than answers in the field of FA metabolism in GBM, and substantial efforts should be made to untangle these complex processes in this intractable disease.
The Journal of Clinical Investigation